Overture Life is an American biotechnology company which seeks to democratize Assisted Reproductive Technologies (ART) by making them more accessible, simplifying techni- ques, and optimizing resources.
Metabolomics was developed by researchers at Overture life as an alternative to invasive genetic analysis of the embryo. It has been found to be 97.5% consistent with the results of invasive genetic analysis.1
In the words of Dr. Jose A. Horcajadas, inventor of the Meta- bolomics test, “the idea is to not only identify the embryos with chromosomal problems, but to also identify the 30% of genetically normal embryos that do not implant. We are on the way to making reproductive medicine less invasive and more effective, for the benefit of all women. Thank you for your participation, your contribution toward the advance- ment of science is much appreciated”.
1 Sara Cabello-Pinedo et al. A novel non-invasive metabolomics approach to screen embryos for aneuploidy. Fertility&Sterility 2020; Vol 114, Issue 3, Supplement, E5-E6